BPC-157/TB-500, in brief. This product puts two separate research peptides in one vial. BPC-157 is a 15-amino-acid peptide copied from part of a gastric juice protein, and in rat studies it helps new blood vessels reach an injury and helps tendon repair cells move in [2,3,4]. TB-500 is the research name for synthetic thymosin beta-4 or a short piece of it; thymosin beta-4 holds spare actin inside cells and, after injury, helps cells crawl into damaged tissue [5,6]. The idea behind pairing them is that two different repair signals might add up. The one controlled study that tested this directly, a 2026 rat Achilles tendon study, found they did not: the combination did no better than either peptide on its own, and only TB-500 alone made the repaired tendon significantly stronger than untreated controls [1]. Neither peptide is an approved drug, and the evidence for both is almost entirely from animals and cells [8]. NextGenPeps supplies the BPC-157/TB-500 blend as 10 mg and 20 mg lyophilised vials for laboratory use only.
What does the BPC-157/TB-500 blend do?
Each peptide in the vial acts on tissue repair in a different way, and the blend is used to study both at once. BPC-157 work centres on blood vessel growth and on repair cells migrating into an injury; thymosin beta-4 work centres on actin, cell movement and new vessels [2,3,5].
In animal and cell studies, that has looked like this:
BPC-157 on its own. Rats with a cut Achilles tendon healed with higher load to failure, better walking function and more collagen than saline controls over 14 days [2].
Thymosin beta-4 on its own. Rat full-thickness skin wounds re-covered with new skin 42% more at day 4 and up to 61% more at day 7 than saline-treated wounds [7].
The two together. In a 2026 rat tendon repair study, the combination improved tissue scores against untreated controls but did not beat either peptide alone, and on tendon strength it scored slightly below each single peptide [1].
NextGenPeps supplies the blend for in vitro research and approved animal studies only. It is not sold as a drug, supplement or diagnostic.
How do BPC-157 and TB-500 work together?
The short answer is that they act on different steps of repair, but no study has shown that those steps add up when the two are combined.
BPC-157. In cultured endothelial cells BPC-157 raised the amount of VEGFR2, the main receptor for the vessel growth factor VEGF, and switched on the Akt and eNOS chain that produces nitric oxide [4]. In rat tendon fibroblasts it did not speed cell division but increased outgrowth, survival under oxidative stress and migration, through the FAK and paxillin adhesion pathway [3].
Thymosin beta-4. Thymosin beta-4 is the major actin-sequestering molecule in cells: it binds single actin units and keeps them ready for the filaments a cell needs to move [5]. Its seven-residue actin-binding motif, LKKTETQ, matched the full protein in endothelial migration and vessel sprouting assays [6].
Together. Vessel growth, cell migration and collagen remodelling are shared end points of both peptides. The authors of the 2026 tendon study suggested that the lack of an added effect may reflect these shared downstream pathways, but they stated that this needs confirmation [1].
What did the combination do in animal studies?
In the only controlled study of the pair, the combination did no better than either peptide alone. Biçer and colleagues cut and surgically repaired the right Achilles tendon in 32 male Sprague-Dawley rats and split them into four groups of eight: untreated control, BPC-157, TB-500, and BPC-157 plus TB-500, each given daily for four weeks. Four tendons per group went to mechanical testing and four to histology [1].
Tendon strength. The repaired tendons were pulled until they failed. Median load to failure was 26.9 N in controls, 37.2 N with BPC-157, 37.4 N with TB-500 and 34.5 N with the combination (Figure 1). Only TB-500 versus control reached significance (adjusted p=0.04); BPC-157 versus control did not (p=0.39), and the combination did not differ from either peptide alone [1].

Figure 1. Repaired tendon strength at four weeks. Median maximum load to failure, n=4 per group, with interquartile ranges. The combination was not stronger than either peptide alone. Source: Biçer et al., 2026.[1]
Tendon tissue. Two pathology scores rate how disorganised healing tendon looks, so lower is better. On the Bonar score (0 to 12) medians were 9.5 for controls, 5.0 for BPC-157, 4.0 for TB-500 and 4.5 for the combination; only TB-500 differed significantly from control (p=0.016). On the Movin score (0 to 24) medians were 18.0, 9.5, 8.0 and 8.0; TB-500 (p=0.017) and the combination (p=0.040) differed from control, BPC-157 did not (Figure 2) [1].

Figure 2. Tendon tissue scores at four weeks. Median total Bonar and Movin scores, n=4 per group; lower means better-organised tissue. TB-500 alone and the combination scored about the same. Source: Biçer et al., 2026.[1]
Collagen. Collagen type I staining did not differ between groups. Collagen type III, the early repair collagen, was highest with TB-500 alone (median H-score 72.5 against 12.5 in controls) and intermediate with the combination (37.5) [1].
The authors called the study exploratory and hypothesis-generating. With four tendons per test, a modest added effect could have been missed, and the paper does not state whether its TB-500 was full-length thymosin beta-4 or a fragment [1].
BPC-157 vs TB-500
They are different molecules, and in the one head-to-head tendon study TB-500 alone did at least as well as BPC-157 alone [1].
Size. BPC-157 is 15 amino acids (1419.5 g/mol). Full-length thymosin beta-4 is 43 residues (4963.5 g/mol); the LKKTETQ fragment also sold as TB-500 is seven residues (about 847 to 889 g/mol).
Origin. BPC-157 is a partial sequence of a gastric juice protein. Thymosin beta-4 occurs in almost every cell [5].
Main studied action. BPC-157: VEGFR2 signalling and tendon fibroblast migration [3,4]. Thymosin beta-4: actin binding, cell migration and new vessel growth [5,6].
In the 2026 tendon study. TB-500 alone significantly raised load to failure and improved the Bonar and Movin scores against controls; BPC-157 alone showed non-significant improvements [1].
What is the BPC-157 and TB-500 pairing called?
The pairing is often called the "Wolverine stack", an informal online nickname rather than a scientific or product name, and NextGenPeps does not use it to describe any effect. The controlled evidence on the combination is limited to the 2026 rat tendon study described above, which found no added benefit over either peptide alone [1].
What is the BPC-157/TB-500 blend made of?
Two peptides, lyophilised together in one vial.
BPC-157 is a linear 15-residue peptide, GEPPPGKPADDAGLV, with formula C62H98N16O22, molecular weight 1419.5 g/mol and CAS number 137525-51-0.
TB-500 is a name used for two different molecules. One is synthetic full-length thymosin beta-4, Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 residues, 4963.5 g/mol, CAS 77591-33-4). The other is the seven-residue actin-binding motif LKKTETQ, residues 17 to 23 of the protein, which is what the FDA's 2026 compounding notices call TB-500 [10]. The two are not interchangeable on a milligram basis.
Which TB-500 is in this blend? Mass spectrometry distinguishes the two forms: a component near 4963 Da is full-length thymosin beta-4, while one near 847 or 889 Da is the LKKTETQ fragment. Identity results for each lot are on its certificate in the NextGenPeps COA library, and studies using this blend should record which form the certificate shows.
BPC-157/TB-500 at a glance
Compound: BPC-157/TB-500 blend, two peptides co-lyophilised in one vial
Class: Synthetic pentadecapeptide (BPC-157) plus a thymosin beta-4 derived peptide (TB-500)
BPC-157 sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV); 1419.5 g/mol
TB-500: Thymosin beta-4 derived peptide; full length is 4963.5 g/mol, the LKKTETQ fragment about 847 to 889 g/mol
Strength: 10 mg or 20 mg blend per vial
Identity and purity: 20 mg lot: identity by LC-MS/MS and purity 99.62% by RP-HPLC at 214 nm (September 25, 2026). 10 mg lot: 99.11% and 99.50% for the two components by UHPLC with mass spectrometry (July 17, 2025). Both certificates are in the COA library
Endotoxin: 20 mg lot under 0.05 EU/ml per USP <85>; the 10 mg lot certificate does not include an endotoxin test
Appearance: White lyophilised powder, sealed vial
Reconstitution: Sterile or bacteriostatic water
Half-life: BPC-157 under 30 minutes in rats and dogs [9]; not established for the blend
Regulatory status: Neither peptide is an FDA-approved drug. Both are prohibited in sport by the World Anti-Doping Agency [12]
Is BPC-157/TB-500 legal or FDA approved?
Neither peptide is an FDA-approved drug, and the blend is sold here only as a research material.
On April 15, 2026, the FDA said it would remove twelve peptides, including BPC-157 and the thymosin beta-4 fragment LKKTETQ ("TB-500"), from Category 2 of its interim list of bulk substances for compounding, the category for substances with significant safety concerns. Removal did not by itself make them eligible for compounding [10]. At its July 23, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500 for compounding. The vote is not binding, and the FDA must still complete rulemaking [11]. These actions concern each peptide as a single substance, not a combination product.
In sport, the World Anti-Doping Agency prohibits BPC-157 as a non-approved substance (class S0) and thymosin beta-4 and its derivatives as growth factor modulators [12].
What is BPC-157/TB-500 used to study?
Researchers use the blend where the question is how two repair signals interact, or whether combining them changes the result.
Combination versus single agents. Tendon repair models with four arms (control, each peptide, both) of the kind used in the 2026 rat study [1].
Tendon and ligament healing. Biomechanical, histological and collagen-typing end points after transection and repair [1,2,8].
Cell migration. Tendon fibroblast outgrowth and FAK-paxillin signalling (BPC-157) alongside actin handling (thymosin beta-4) [3,5].
Angiogenesis. VEGFR2 signalling and endothelial sprouting assays [4,6].
Wound healing. Skin wound closure models where thymosin beta-4 has documented effects [7].
Buying BPC-157/TB-500 for research: what each vial includes
Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library. The current 20 mg lot was tested on September 25, 2026: identity by LC-MS/MS, purity by RP-HPLC at 214 nm (99.62%), content by HPLC quantitation, and endotoxin under 0.05 EU/ml per USP <85>. The current 10 mg lot was tested on July 17, 2025 by UHPLC with mass spectrometry, at 99.11% and 99.50% for its two components.
Verified identity and purity. Over 99% purity on both current lots, with endotoxin results on the 20 mg certificate.
Two strengths. 10 mg and 20 mg vials of lyophilised blend.
US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.
Research use only. The blend is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, supplement or diagnostic.
BPC-157/TB-500 handling, storage and analytical notes
Format. Supplied as lyophilised powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be taken from the studies above.
Storage. The lot certificates record storage at 2 to 8 °C. Keep the sealed vial cold and protected from light and moisture. After reconstitution, hold the solution at 2 to 8 °C and avoid repeated freeze-thaw cycles.
Two components, one solution. Once reconstituted, both peptides share the same solution, so their ratio is fixed by the vial. Experiments that need to vary one peptide independently, or to include single-peptide arms as in the 2026 study, need the separate products.
Identity check. Mass spectrometry should show BPC-157 near 1419 Da, and the TB-500 component either near 4963 Da (full-length thymosin beta-4) or near 847 or 889 Da (LKKTETQ fragment).
Naming. BPC-157/TB-500 and BPC-157 + TB-500 both refer to this pairing. Other blends add GHK-Cu or KPV and are different products.
What is not established about BPC-157/TB-500
A combined benefit. The only controlled study found no added effect over either peptide alone, in one rat tendon model with four tendons per test [1].
Which TB-500 the studies used. The 2026 tendon study does not state whether its TB-500 was full-length thymosin beta-4 or a fragment, while the rat wound results for thymosin beta-4 used the full protein [1,7].
Interaction in solution. No published data address the stability of the two peptides stored together after reconstitution.
Long-term and clinical effects. There are no controlled clinical data for either peptide in tendon repair, and BPC-157 animal studies have not run beyond six weeks [8].
Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.